ESMO 2022 | LEAP-015: lenvatinib + pembrolizumab + mFOLFOX6 in advanced/met gastroesophageal adenocarcinoma

Kohei Shitara, National Cancer Center Hospital East, Kashiwa, Japan talks about the rationale and trial design of the Phase III LEAP-015 (NCT04662710) trial, randomized clinical study investigating the efficacy and safety of lenvatinib plus pembrolizumab plus mFOLFOX6 in patients with advanced gastroesophageal cancer. The trial consists of two parts; part one is treatment with lenvantinib in combination with pembrolizumab and chemotherapy; part two is randomization to receive lenvatinib plus pembrolizumab plus chemotherapy, or chemotherapy alone. Primary endpoints include overall-survival (OS) and progression-free survival (PFS). This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.